This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event, 7 - 9 June, 2022
Live In-Person Event: 7 - 9 June, Postillion Hotel AmsterdamDigital Experience: All Sessions Livestreamed 7 - 9 June

Ulf Landegren, MD, PhD
Professor, Dept. of Immunology, Genetics and at Uppsala University


Ulf Landegren received his MD and PhD in Uppsala, Sweden, before spending five years at California Institute of Technology. As professor of molecular medicine in Uppsala his research focuses on developing molecular tools to meet important medical needs, first focused on analyzing genetic variation with techniques such as oligonucleotide ligation assays and padlock probes. In later work his lab showed that pairs of oligonucleotide-conjugated antibodies can allow high- throughput, high-performance analysis of protein expression levels in liquid samples and for imaging their distribution in situ by developing a family of proximity ligation assays.

Professor Landegren is a member of EMBO, the Royal Swedish Academy of Sciences, the European Academies’ Scientific Advisory Committee (EASAC), and the Royal Society of Sciences at Uppsala. He is member of several academic or industrial boards and advisory boards. He has authored 224 peer-reviewed publications, and he is inventor of 46 patents or applications. Work in his lab has so far given rise to 12 spin-out companies with a combined staff of more than 500 people, including two companies that are now publicly traded (Olink Proteomics and Q-linea). Technologies from his lab have been licensed to many leading international biotech and diagnostic companies.

Agenda Sessions

  • Dual-recognition Protein Assays